Ohm Labs violations draw warning letter
This article was originally published in The Tan Sheet
Executive SummaryFDA sends a follow-up warning letter to Ohm Laboratories regarding several good manufacturing practice violations. The agency identified the violations during a July and August 2009 inspection of the company's Gloversville, N.Y., facility. The OTC manufacturer, a subsidiary of Indian pharma Ranbaxy, insufficiently addressed the violations in a Sept. 11 letter, the agency said in its Dec. 21 warning. Specifically, the company's methods, facilities or controls used to manufacture, process, pack and/or hold products do not conform to GMP regs. For example, the firm failed to identify a conclusive root cause for the contamination of several products and did not extend the investigation into batches of similarly treated products. FDA seeks an immediate response from Ohm or else it will seek legal action. Ohm acknowledged receiving the initial warning in a Dec. 24 statement (1"The Tan Sheet" Jan. 11, 2010, In Brief)
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.